CMAB Biopharma grabs $38 mln Series A
CMAB Biopharma Inc, a Chinese provider of process development and manufacturing services for biologic products, has raised $38 million in Series A financing. C-Bridge Capital and BioBAY led the round with participation from I-Bridge Capital and Qianhai FoF.
2 January 2018•1 min read
